BioMarin options flow shows large bullish call spread targeting $100 by April 2027
BioMarin Pharmaceutical (BMRN) saw significant bullish options activity, with a 182:1 call-to-put ratio. A large call spread bet targets $100 by April 2027, indicating confidence in a 37% upside. Recent earnings beats and pipeline developments support this outlook, though competitive risks remain. Technical indicators also suggest strong momentum.
How this was made
The 30-second read
Why it matters
The flow suggests a speculative upside view, but the distant expiry and high target reduce immediate trade certainty.
Market read
Unusual options activity may signal upcoming price movement, relevant for traders monitoring biotech momentum.
What to watch
Potential competitive pressure on Voxzogo and the long timeline to April 2027 may dilute the trade's relevance.
Background
Options flow analysis of BioMarin Pharmaceutical Inc. (BMRN) showing a large bullish call spread and rising implied volatility.
Ticker impact
Unusual bullish call spread on BioMarin (182:1 call-to-put ratio) opened with 1,000 contracts per leg, indicating a directional bet on the stock.
Possible short-term price lift as the options activity may attract speculative buying.
Options flow is a leading indicator; the size and skew are uncommon, but the target is far out (7 months) and the stock is still far from $90.
Market effects
Highlights bullish sentiment in biotech sector, may influence peer stocks.
US biotech market focus; limited regional effect.
Minimal global impact beyond biotech investors.
Counterpoint
The $90 strike is 37% above current price; the bet may be overly optimistic and could fail if catalysts stall.
Key entities
- companyBioMarin Pharmaceutical Inc.
US-listed biotech company (ticker BMRN).
